Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

y and equipment - net 208,742 162,683

State research and development tax credit

exchange receivable - net of current portion 2,250 1,500

Other assets 549 548

Total $399,248 $543,443

Liabilities and Stockholders' Equity

Current liabilities $61,958 $67,558

Other liabilities - 24

Senior convertible notes 112,004 111,761

Stockholders' equity 225,286 364,100

Total $399,248 $543,443


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., , REDWOOD CITY, Calif., Nov. 24 /PRNe... GHDX ) today announced that Randy Scott, Genomic...21st Annual Piper Jaffray Health Care Conference i...:00 a.m. ET. ,, To access the live and subsequ...the Investor Relations section of Genomic Health,s...
(Date:11/24/2009)..., Program Connects Custom... Samples Collected with DNA Genotek Products , ...24, 2009 -- DNA Genotek , a leading provider of p...ation and preparation, today announced its new glo...t enhancements for DNA Genotek,s partner community...
(Date:11/24/2009)..., , SEATTLE, Nov. 24 /PRNewswire-Firs...d MTA: CTIC) management will present at the 21st A...nference will be held December 1-2, 2009, at the N...Tuesday, December 1 at 11:00 a.m. Eastern Time in ...s presentation will be available at www.cellthera...
(Date:11/23/2009)..., CHAMPAIGN, Ill. You can think of it as origami...iversity of Illinois have developed a technique fo...e silicon structures from thin films by coupling p...by capillary interactions. , The films, only a fe... is not possible with thicker pieces of the same m...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
... 12 Anthera Pharmaceuticals, Inc., a,privately he...mmatory drugs,announced today that it has complete...urrent Acute coronary events with Near-term Cardio...designed to examine the impact of,varespladib (A-0...of an Acute,Coronary Syndrome (ACS) event. , "...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced toda...have agreed with the FDA on the final design for a... of hepatitis C (HCV), slated to initiate in the f...at R7128 is advancing into a large phase 2b trial,...ief Medical Officer. "R7128 is the most advanced n...
...nuary 12 , - Reflects Strong International Gr...ding IP Management Specialist and Legal Support Se...llectual property,( http://www.cpaglobal.com ) (IP...outsourced legal support services, has today marke...ew brand worldwide. , Founded in 1969 as a spe...
Other Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
(Date:11/25/2009)...ital to your health as what you eat, found researc... Their experiments in mice revealed that the daily...verthe body,s metabolic clearinghouseis mostly con...dian clock as conventional wisdom had it. , "If...umber of genes completely independent of the circa...
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 1Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 2Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 3Go to the doctor 3F Only if Im really sick 52314 1Go to the doctor 3F Only if Im really sick 52314 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3
...ngs about the causes of mad cow disease show that ...also in the genes of cattle," said Juergen A. Rich...edicine and Pathobiology at Kansas State Universit...al years ago, Richt said, it was thought that the ...thy -- also called BSE or mad cow disease -- was a...
...Stevens Institute of Technology has been awarded a...e project, "MRI: Acquisition of an Inductively Cou...abrication." The Stevens team includes Yong Shi, t...gineering department; Stefan Strauf, a Professor t...e Professor in the Mechanical Engineering departme...
...t Service Southern Research Station (SRS) today an...t Disturbances: Wildfires, Storms, and Invasive Sp...ffers a synthesis of new approaches to understandi...s. , The Economics of Forest Disturbances is th...e framework for analyzing the economic effects of ...
Other Biology News:K-State professor's USDA research shows mad cow disease also caused by genetic mutation 2NSF awards two grants to Stevens for nano/micro device fabrication and nano sensor development 2Book breaks new ground in the study of economics and forest threats management 2
GIBCO Fetal Bovine Serum Heat-Inactivated from Invitrogen
Mouse Anti-EGFr VIII Antibody, Unconjugated from Invitrogen
Custom siRNA, PAGE purified from Ambion
GIBCO Kanamycin Sulfate from Invitrogen
Biology Products: